Welcome to our dedicated page for Selecta Biosciences news (Ticker: SELB), a resource for investors and traders seeking the latest updates and insights on Selecta Biosciences stock.
Selecta Biosciences, Inc. (NASDAQ: SELB) pioneers novel biologic therapies using its proprietary SVP™ technology platform to address severe diseases with unmet medical needs. This page serves as the definitive source for verified updates on clinical developments, research breakthroughs, and strategic collaborations.
Access timely updates on SELB's Phase 2 trials for SEL-212 in severe gout and Phase 1 studies of SEL-403 targeting mesothelioma. Stay informed about advancements in gene therapy candidates for metabolic disorders and progress with the RNA Armory® platform for autoimmune treatments.
Our curated news stream covers essential updates including clinical trial milestones, regulatory filings, partnership announcements, and scientific presentations. Investors and researchers will find structured information on SELB's approach to immune tolerance and its implications for therapeutic efficacy.
Bookmark this resource for objective reporting on Selecta Biosciences' progress in redefining biologic treatments. Check regularly for analysis-neutral updates on pipeline developments directly impacting patient care and biopharmaceutical innovation.
Selecta Biosciences, Inc. (NASDAQ: SELB) announced its participation in the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The company will provide a corporate update and engage in one-on-one investor meetings. The presentation is scheduled for May 24, 2022, at 7:00 a.m. ET. Selecta is focused on developing tolerogenic therapies via its ImmTOR® platform to treat autoimmune diseases and enhance gene therapies. Investors can access a webcast of the presentation and archived materials on their official website.
Selecta Biosciences, Inc. (NASDAQ: SELB) reported a robust financial performance for Q1 2022, with net income of $28.8 million compared to a loss of $24.6 million in Q1 2021. The company completed an underwritten offering, raising $38.7 million, extending its cash runway into mid-2024, with a total cash position of $154.2 million. Key milestones include the initiation of the Phase 1 trial for SEL-302 in H2 2022 and completion of the Phase 3 DISSOLVE studies by Q4 2022, with joint topline results expected in Q1 2023.
Selecta Biosciences, Inc. (NASDAQ: SELB) announced six upcoming presentations at the 25th Annual Meeting of the American Society of Gene & Cell Therapy, demonstrating the capabilities of its ImmTOR® platform. Key highlights include oral presentations about the immune response to AAV gene therapies and their efficacy, along with poster presentations focusing on the combination of ImmTOR® with other therapies. The company anticipates initiating a Phase 1 clinical trial for treating methylmalonic acidemia, showcasing ongoing efforts to enhance gene therapy through immunological advancements.
On April 28, 2022, Selecta Biosciences, Inc. (NASDAQ: SELB) announced a conference call scheduled for May 5, 2022, at 8:30 a.m. ET to discuss its financial results for Q1 2022, which ended on March 31, 2022. The company focuses on developing tolerogenic therapies using its ImmTOR® platform, aimed at mitigating unwanted immune responses. Stakeholders can participate via telephone or access the live and archived webcast on the company’s website.
Selecta Biosciences, Inc. (NASDAQ: SELB) announced a public offering of 27,428,572 shares of its common stock, along with warrants for an additional 20,571,429 shares, at a price of $1.41 per share. The warrants have an exercise price of $1.55 and expire in five years. Selecta expects to generate gross proceeds of approximately $38.7 million from this offering, with the close anticipated on April 11, 2022. The offering is conducted under a previously filed shelf registration statement with the SEC.
On April 4, 2022, Selecta Biosciences (NASDAQ: SELB) announced its participation in the 21st Annual Needham Virtual Healthcare Conference from April 11-14, 2022. The company will hold a fireside chat and engage in one-on-one investor meetings. The chat is scheduled for April 14, 2022, at 1:30 p.m. EST. Interested parties can access a live webcast through Selecta's website. Selecta operates using its clinically validated ImmTOR® platform to develop therapies that address unwanted immune responses.
The FDA has lifted the clinical hold on Selecta's SEL-302 for treating methylmalonic acidemia, enabling the company to initiate Phase 1 trials. Selecta reported a net loss of $25.7 million for 2021, an improvement from a loss of $68.9 million in 2020. Revenue surged to $85.1 million, primarily from licensing agreements, compared to $16.6 million in the previous year. The company's cash position is strong with $129.4 million expected to last into Q3 2023, supporting its growing pipeline, including advancements in SEL-212 for chronic refractory gout and SEL-399 for gene therapy.
Selecta Biosciences, Inc. (NASDAQ: SELB) announced a conference call scheduled for March 10, 2021, at 8:30 a.m. ET to discuss its financial results for the quarter and full-year ending December 31, 2021. The call will provide a business update related to its ImmTOR® platform, which aims to develop therapies that manage unwanted immune responses. Investors can join via phone or access the live and archived webcast through the company’s website. Selecta is focused on enzyme therapies, gene therapies, and autoimmune diseases.
Selecta Biosciences (NASDAQ: SELB), based in Watertown, MA, will share a corporate update and hold one-on-one investor meetings at the SVB Leerink 11th Annual Global Healthcare Conference from February 14-18, 2022. The presentation is scheduled for February 18, 2022, at 1:00 p.m. EST. Selecta is known for its ImmTOR™ platform, which is utilized to develop tolerogenic therapies aimed at reducing unwanted immune responses. An archived webcast will be available for those interested in further information.
Selecta Biosciences (Nasdaq: SELB) and Ginkgo Bioworks (NYSE: DNA) have announced a collaboration aimed at advancing gene therapy delivery through the development of next-generation viral capsids. Utilizing Ginkgo’s cell engineering expertise and Selecta’s ImmTOR platform, the partnership seeks to enhance transduction, tissue tropism, and reduce immunogenicity. Ginkgo stands to earn up to $1.1 billion in milestone payments, including Selecta common stock. This collaboration could address significant challenges in gene therapy, potentially benefiting millions of patients.
